{"news_desk": "Letters", "print_page": null, "section_name": "Opinion", "subsection_name": null, "byline": [], "abstract": null, "type_of_material": "Letter", "word_count": "156", "lead_paragraph": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "pub_date": "2016-03-12T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Cancer Drug Dosing", "content_kicker": "Letter", "print_headline": "Cancer Drug Dosing", "kicker": "Letter"}, "snippet": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "multimedia": [], "web_url": "http://www.nytimes.com/2016/03/12/opinion/cancer-drug-dosing.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Cancer", "name": "subject"}], "blog": [], "_id": "56e3375438f0d81b768a681b", "source": "The New York Times"}